Penumbra, Inc.

Penumbra, Inc.

PEN

$319.39

Updated: 23/09/2026, 09:37:45

Market Cap
$12.58B
Sector
Healthcare
Industry
Medical - Devices
Country
US
Stock valuation chart
One-year closing share-price history for PEN
Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

USD
NYSE
CEO: Adam Elsesser
Employees: 4,700
https://www.penumbrainc.com
Asset Summaries
Latest generated summaries for PEN

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for PEN.
Share price
$319.39
Market cap
$12.58B
Exchange
NYSE
Currency
USD
CEO
Adam Elsesser
Employees
4,700
IPO date
18/09/2015
Beta
0.698
Last dividend
$0.00
Day range
$318.49 – $319.80
52-week range
$221.26 – $362.41
1-day performance
0.19%
1-year performance
44.35%
Current drawdown (1Y)
-11.87%
CIK
0001321732
CUSIP
70975L107
ISIN
US70975L1070
Created
07/12/2025, 05:43:26
Last update
23/09/2026, 09:37:45

Track Penumbra, Inc. with an AI analyst

See which prediction-market events move PEN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.